The Future of Decision-Making in Colorectal Cancer: ctDNA’s Emerging Role

home / around-the-practice / the-future-of-decision-making-in-colorectal-cancer-ctdna-s-emerging-role

A panel of experts review the historically available treatment decision-making tools for patients with colorectal cancer and discuss the current and future use of minimal residual disease (MRD) and circulating tumor DNA (ctDNA) testing as it relates to key clinical trial data.

Patient Scenario: A 64-Year-Old Man with Stage II Colon Cancer

EP. 1: Patient Scenario: A 64-Year-Old Man with Stage II Colon Cancer

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Stacey A. Cohen, MD;Aparna Raj Parikh, MD, MS
February 10th 2023

Tanios S. Bekaii-Saab, MD, presents a patient scenario of a 64-year-old man with stage 2 (pT3N0) colon cancer to the panel for discussion.

Considering a Patient with Colorectal Cancer for Adjuvant Chemotherapy

EP. 2: Considering a Patient with Colorectal Cancer for Adjuvant Chemotherapy

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Stacey A. Cohen, MD;Aparna Raj Parikh, MD, MS
February 10th 2023

Aparna Parikh, MD, MS, details when she would recommend adjuvant chemotherapy to patients with similar presentations of colorectal cancer.

Over- and Under-Treatment of Stage II and III Colorectal Cancer in the Adjuvant Setting

EP. 3: Over- and Under-Treatment of Stage II and III Colorectal Cancer in the Adjuvant Setting

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Stacey A. Cohen, MD;Aparna Raj Parikh, MD, MS
February 16th 2023

Stacey A. Cohen, MD, and Daniel H. Ahn, DO, describe the challenges of deciding which patients with colorectal cancer should receive adjuvant therapy, and the risk of over- and under-treatment in later stages.

Monitoring a Patient with Colorectal Cancer After Adjuvant Therapy

EP. 4: Monitoring a Patient with Colorectal Cancer After Adjuvant Therapy

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Stacey A. Cohen, MD;Aparna Raj Parikh, MD, MS
February 16th 2023

Dr Stacey A. Cohen discusses how she typically monitors patients with stage II and III colorectal cancer during and after adjuvant therapy.

Testing for Minimal Residual Disease (MRD) in Patients with Colorectal Cancer

EP. 5: Testing for Minimal Residual Disease (MRD) in Patients with Colorectal Cancer

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Stacey A. Cohen, MD;Aparna Raj Parikh, MD, MS
February 24th 2023

Dr Aparna Parikh explains minimal residual disease (MRD) in colorectal cancer and the logistical challenges of MRD testing.

Emerging Biomarkers for Assessing Therapy Response in Colorectal Cancer

EP. 6: Emerging Biomarkers for Assessing Therapy Response in Colorectal Cancer

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Stacey A. Cohen, MD;Aparna Raj Parikh, MD, MS
February 24th 2023

The panel discusses other emerging biomarkers for monitoring patient response to therapy for colorectal cancer.

Circulating Tumor DNA and its Use in Colorectal Cancer Treatment Decision-Making

EP. 7: Circulating Tumor DNA and its Use in Colorectal Cancer Treatment Decision-Making

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Stacey A. Cohen, MD;Aparna Raj Parikh, MD, MS
March 3rd 2023

Aparna Parikh, MD, MS, defines circulating tumor DNA (ctDNA) and the use of ctDNA assays in colorectal cancer.

Tumor-Naïve vs Tumor-Informed ctDNA Analyses in CRC Biomarker Testing

EP. 8: Tumor-Naïve vs Tumor-Informed ctDNA Analyses in CRC Biomarker Testing

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Stacey A. Cohen, MD;Aparna Raj Parikh, MD, MS
March 3rd 2023

Dr Daniel H. Ahn explains the logistical concerns of ctDNA testing in colorectal cancer.

Utilizing ctDNA Assays in Colorectal Cancer for Treatment and Monitoring of Patients with Solid Tumors

EP. 9: Utilizing ctDNA Assays in Colorectal Cancer for Treatment and Monitoring of Patients with Solid Tumors

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Stacey A. Cohen, MD;Aparna Raj Parikh, MD, MS
March 10th 2023

The panel reviews the different settings in colorectal cancer where ctDNA is being investigated as a tool for treatment and monitoring.

Key Clinical Trial Data on ctDNA Assays in Colorectal Cancer

EP. 10: Key Clinical Trial Data on ctDNA Assays in Colorectal Cancer

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Stacey A. Cohen, MD;Aparna Raj Parikh, MD, MS
March 10th 2023

Stacey A. Cohen, MD, and Aparna Parikh, MD, MS, review the design and outcomes of key clinical trials exploring the use of ctDNA assays in colorectal cancer.

The Evolution of ctDNA Assays in Colorectal Cancer

EP. 11: The Evolution of ctDNA Assays in Colorectal Cancer

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Stacey A. Cohen, MD;Aparna Raj Parikh, MD, MS
March 17th 2023

The panel comments on how they see ctDNA assay usage evolving in colorectal cancer management.

Final Comments on ctDNA Testing in the Management of Colorectal Cancer

EP. 12: Final Comments on ctDNA Testing in the Management of Colorectal Cancer

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Stacey A. Cohen, MD;Aparna Raj Parikh, MD, MS
March 17th 2023

The panel shares some closing thoughts on ctDNA testing in patients with colorectal cancer.